Alx Oncology Holdings (ALXO) Consolidated Net Income (2019 - 2026)

Alx Oncology Holdings' Consolidated Net Income history runs 8 years deep, the most recent figure standing at -$18.1 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 41.08% year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at -$89.0 million (up 31.52% YoY), while the FY2025 annual figure was -$101.7 million, up 24.18% from the prior year.
• Consolidated Net Income came in at -$18.1 million for Q1 2026 at Alx Oncology Holdings, up from -$22.8 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $91.1 million in Q4 2023 to a low of -$51.0 million in Q3 2023.
• A 5-year average of -$23.7 million and a median of -$30.6 million in 2022 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income tumbled 1555.03% in 2022 and surged 397.18% in 2023, its largest moves.
• Alx Oncology Holdings' Consolidated Net Income stood at -$30.6 million in 2022, then soared by 397.18% to $91.1 million in 2023, then sank by 132.02% to -$29.2 million in 2024, then advanced by 21.71% to -$22.8 million in 2025, then increased by 20.66% to -$18.1 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$18.1 million, -$22.8 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison